SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-23-068264
Filing Date
2023-08-16
Accepted
2023-08-16 17:00:13
Documents
13
Period of Report
2023-08-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea183702-8k_virpaxpharm.htm   iXBRL 8-K 29569
2 AMENDMENT TO EMPLOYMENT AGREEMENT, DATED AUGUST 15, 2023, BY AND BETWEEN VIRPAX ea183702ex10-1_virpaxpharm.htm EX-10.1 10866
  Complete submission text file 0001213900-23-068264.txt   219405

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE vrpx-20230815.xsd EX-101.SCH 3027
4 XBRL LABEL FILE vrpx-20230815_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE vrpx-20230815_pre.xml EX-101.PRE 22367
7 EXTRACTED XBRL INSTANCE DOCUMENT ea183702-8k_virpaxpharm_htm.xml XML 3420
Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-4597
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 231178879
SIC: 2834 Pharmaceutical Preparations